Drug Interactions, Pharmacokinetics
Conditions
Keywords
Daptomycin, Rifampin, P-glycoprotein, Pharmacokinetic
Brief summary
The purpose of this study is to understand how an antibiotic, rifampin, may change the blood levels of another antibiotic, daptomycin, in the body. In addition, the effect of polymorphisms in P-glycoprotein (a protein involved in the removal of daptomycin from the body) on the blood levels of daptomycin will be evaluated. The hypotheses are that rifampin will decrease the blood levels of daptomycin and that the effect will be greater for certain P-glycoprotein polymorphisms.
Detailed description
This will be an open-label, sequential pharmacokinetic study in 12 healthy volunteers. After providing informed consent, participants meeting inclusion criteria will be administered daptomycin 6 mg/kg over 2 minutes and blood and urine samples will be collected over a 24 hour period after infusion. Following this, participants will be given a 13 day supply of rifampin 600 mg/day to be taken at home. After completion of the rifampin course, a second pharmacokinetic sampling will be performed (day 15 overall). Participants will be administered a dose of rifampin 600 mg then once again be administered daptomycin 6 mg/kg over 2 minutes and blood and urine samples will be collected over a second 24 hour period. A blood sample will be obtained at the first study visit for determination of each participant's P-glycoprotein genotype.
Interventions
DRUGDaptomycin
DRUGRifampin
Sponsors
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
University of Utah
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Ability to provide informed consent * If female of child bearing potential, on reliable method of contraception and negative pregnancy test at enrollment
Exclusion criteria
* Obesity (body mass index \> 30) * Creatinine clearance \< 80 ml/min * Creatine phosphokinase \> 2 times upper limit of normal at enrollment * Aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase \> 3 times upper limit of normal at enrollment * History of liver disease or cirrhosis * History of congestive heart failure * Allergy or intolerance to rifampin or daptomycin * Need for concomitant non-study medications during the study period * Inability to abstain from grapefruit juice or herbal supplements (such as St. John's wort) during the study period * Receipt of study drugs within 30 days prior to enrollment * Pregnancy or lactation * Inability to adhere to study procedures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent Protein Binding of Daptomycin | 14 days | The percent protein binding of daptomycin before and after administration of rifampin |
| Daptomycin Free and Total Area Under the Concentration-Time Curve (AUC) from 0 to 24 hours | 14 days | The free and total AUC from 0 to 24 hours of daptomycin before and after administration of rifampin |
| Daptomycin Free and Total AUC from 0 to Infinity | 14 days | The free and total AUC from 0 to infinity of daptomycin before and after administration of rifampin |
| Daptomycin Free and Total Peak Concentrations | 14 days | The free and total peak concentrations of daptomycin before and after administration of rifampin |
| Daptomycin total, renal, and non-renal clearance | 14 days | Total, renal, and non-renal clearance of daptomycin before and after administration of rifampin |
| Daptomycin Volume of Distribution | 14 days | The volume of distribution of daptomycin before and after administration of rifampin |
| Daptomycin Elimination Rate Constant | 14 days | The elimination rate constant of daptomycin before and after administration of rifampin |
| Daptomycin Free and Total 24 hour Concentrations | 14 days | The free and total 24 hour concentrations of daptomycin before and after administration of rifampin |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Adverse Events | 45 days | Safety monitoring will be done by regular adverse event assessment, laboratory and vital sign monitoring, and physical exam. |
| P-glycoprotein Polymorphism | 14 days | The effect of different P-glycoprotein polymorphisms on the pharmacokinetic profile of daptomycin before and after administration of rifampin will be assessed |
Countries
United States
Outcome results
None listed